After three-month delay, Amgen’s Lumakras clinches FDA green light in colorectal cancer

Am­gen’s Lumakras has se­cured an FDA ap­proval in com­bi­na­tion with the drug­mak­er’s Vectibix for a sub­set of pa­tients with metasta­t­ic col­orec­tal can­cer, mark­ing a pos­i­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.